Framebased-Frameless_DV_2017

CONCLUSIONS

• Small patient numbers treated in prospective trials

• Local tumor control appears favourable

• Very limited overall survival, similar to Cx only

• High rates of severe GI toxicity

SBRT with moderate intensity to complement

systemic Tx with effective but well tolerated

local Tx

Should not be practiced outside of

prospective trials

ESTRO SBRT 2017 - Matthias Guckenberger